| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/LEU.2014.69 |
| P698 | PubMed publication ID | 24518207 |
| P2093 | author name string | E Evans | |
| C J Kirk | |||
| J Singh | |||
| W F Westlin | |||
| Y Mishima | |||
| A J Yee | |||
| H Eda | |||
| L Santo | |||
| N Nemani | |||
| N S Raje | |||
| D D Cirstea | |||
| P R Waterman | |||
| S Arastu-Kapur | |||
| T A Scullen | |||
| P2860 | cites work | Activation of Arp2/3 complex-mediated actin polymerization by cortactin | Q24290885 |
| Multiple myeloma | Q24655964 | ||
| TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
| Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays | Q40749337 | ||
| Genetic analysis of tyrosine kinase function in B cell development | Q41039677 | ||
| Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. | Q41494300 | ||
| The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages | Q41510794 | ||
| Skeletal complications of malignancy | Q41637486 | ||
| Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs | Q41963512 | ||
| Effect of protein kinase C and Ca(2+) on p42/p44 MAPK, Pyk2, and Src activation in rat conjunctival goblet cells | Q42085741 | ||
| Autoamplification of NFATc1 expression determines its essential role in bone homeostasis | Q42972503 | ||
| Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins | Q43670938 | ||
| Bone-Resorbing Activity in Supernatants from Lymphoid Cell Lines | Q43676962 | ||
| PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption | Q44270131 | ||
| The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. | Q44431651 | ||
| Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. | Q45861548 | ||
| Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma | Q46158177 | ||
| Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. | Q46711436 | ||
| Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis | Q47761859 | ||
| Evidence for the secretion of an osteoclast stimulating factor in myeloma. | Q53791263 | ||
| Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. | Q54655741 | ||
| Pathogenesis of myeloma bone disease. | Q55052458 | ||
| Pathologic fractures correlate with reduced survival in patients with malignant bone disease | Q80974012 | ||
| Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling | Q28571577 | ||
| Roles of protein kinase C, Ca2+, Pyk2, and c-Src in agonist activation of rat lacrimal gland p42/p44 MAPK | Q28576012 | ||
| Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice | Q29547898 | ||
| Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts | Q29618116 | ||
| Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia | Q30195143 | ||
| Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements | Q30990490 | ||
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma | Q33402536 | ||
| An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma | Q33403690 | ||
| Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety | Q33405602 | ||
| CaM kinase II: a protein kinase with extraordinary talents germane to insulin exocytosis | Q33548178 | ||
| Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease | Q33740176 | ||
| The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective | Q33996259 | ||
| The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases | Q34355151 | ||
| Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells | Q35080394 | ||
| Bone anabolic agents for the treatment of multiple myeloma | Q35603116 | ||
| Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma | Q35915726 | ||
| MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. | Q36141697 | ||
| Bone marrow microenvironment and the identification of new targets for myeloma therapy | Q36162703 | ||
| Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma | Q36206430 | ||
| Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma | Q36384889 | ||
| The pathogenesis of the bone disease of multiple myeloma. | Q37136324 | ||
| The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. | Q37166798 | ||
| Clear zone in osteoclast function: role of podosomes in regulation of bone-resorbing activity | Q37202816 | ||
| Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts | Q37374745 | ||
| PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase | Q37384701 | ||
| Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study | Q37397995 | ||
| Tumor-host cell interactions in the bone disease of myeloma | Q37771082 | ||
| Novel bone-targeted strategies in oncology | Q37774141 | ||
| Multiple myeloma: biology of the disease | Q37815266 | ||
| Ibrutinib in chronic lymphocytic leukemia and B cell malignancies | Q38105129 | ||
| The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells | Q38346139 | ||
| Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy | Q39192989 | ||
| Serum calcium-decreasing factor, caldecrin, inhibits receptor activator of NF-κB ligand (RANKL)-mediated Ca2+ signaling and actin ring formation in mature osteoclasts via suppression of Src signaling pathway | Q39371983 | ||
| Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans | Q39412429 | ||
| P433 | issue | 9 | |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 1892-1901 | |
| P577 | publication date | 2014-02-12 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity | |
| P478 | volume | 28 |
| Q50888455 | Bone Disease in Multiple Myeloma. |
| Q35260732 | Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma |
| Q38834459 | Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. |
| Q37427124 | Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses |
| Q29248430 | Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions |
| Q26738946 | Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience |
| Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
| Q42009130 | Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid |
| Q38598342 | Myeloma and Bone Disease |
| Q58790080 | Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1 |
| Q42101609 | Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia |
| Q40111192 | Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease |
| Q34448984 | Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells. |
| Q26795594 | Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms |
| Q38302987 | Role of decorin in multiple myeloma (MM) bone marrow microenvironment |
| Q35860566 | The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway |
| Q33918020 | The effects of proteasome inhibitors on bone remodeling in multiple myeloma |
Search more.